Exploratory analysis of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER-2) PIK3CA mutated (mut) advanced breast cancer (aBC) treated with taselisib (TAS) and/or fulvestrant (FUL) reveals increased CCNE2 expression with poor outcome to placebo (PBO) plus FUL but not TAS plus FUL in SANDPIPER